ArticleJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons2013
Absence of exposed bone following dental extraction in beagle dogs treated with 9 months of high-dose zoledronic acid combined with dexamethasone.
Article in Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Zoledronic acid inhibits osteoclastogenesis and bone resorptive function by suppressing RANKL‑mediated NF‑κB and JNK and their downstream signalling pathways.Molecular medicine reports · 2022Article
- Review
- Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.International journal of implant dentistry · 2021Review
- Pyk2 deficiency enhances bone mass during midpalatal suture expansion.Orthodontics & craniofacial research · 2020Article
- Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.Bone research · 2020Review
- Medication-related osteonecrosis of the jaw after long-term bisphosphonate treatment in a cat.Journal of veterinary internal medicine · 2019Article
- Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.Current osteoporosis reports · 2018Review
- Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.The Journal of international medical research · 2018Review
- Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.Current osteoporosis reports · 2016Review
- Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.Clinical oral investigations · 2016Article
- OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- Non-Radiation-Related Osteonecrosis of the Jaws in Dogs: 14 Cases (1996-2014).Frontiers in veterinary science · 2015Article
- Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide.Medicina oral, patologia oral y cirugia bucal · 2014Article
- RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2014Article
- Early effects of parathyroid hormone on bisphosphonate/steroid-associated compromised osseous wound healing.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014Article
- Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness.Bone · 2013Article
- Bone vascularization in normal and disease conditions.Frontiers in endocrinology · 2013Article
Corrections and comments
- Commented on byIn reply.2013
- Commented on by
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purposeFactors contributing to osteonecrosis of the jaw with anti-remodeling drug treatment are unclear. Epidemiologic and experimental studies have suggested the combination of bisphosphonates and dexamethasone results in osteonecrosis of the jaw more often than either agent alone. The goal of this study was to assess the combination of these 2 drugs in a large animal model previously shown to be susceptible to exposed bone in the oral cavity when treated with bisphosphonates. MATERIALS AND
methodsSkeletally mature beagle dogs were untreated controls or treated with zoledronic acid (ZOL), dexamethasone (DEX), or ZOL plus DEX. ZOL and DEX were given at doses based on those used in humans. All animals underwent single molar extraction at 7 and 8 months after the start of the study. Extraction sites were obtained at month 9 for assessment of osseous healing using micro-computed tomography and histology.
resultsNo animals were observed to have exposed bone after dental extraction, yet 1 animal treated with ZOL and 1 treated with ZOL plus DEX had severely disrupted extraction sites as viewed by computed tomography and histology. These 2 animals had an intense periosteal reaction that was less obvious but still present in all ZOL-treated animals and absent from untreated animals. There was no significant difference in bone volume within the socket among groups at 4 or 8 weeks after healing, yet the ratio of surface to volume was significantly higher in animals treated with ZOL plus DEX at 8 weeks compared with control animals.
conclusionsThese findings suggest a more complex pathophysiology to osteonecrosis of the jaw than is implied by previous epidemiologic studies and those in rodents and raise questions about the potential role of DEX in its etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.